ITM shares details of radiopharma's phase 3 win, reveals overall survival miss
ITM Isotope Technologies has provided more detail on how its lead radiotherapy bested the standard of care in a recent phase 3 study while revealing that the candidate was unable to prove a benefit in median overall survival.
ITM Isotope Technologies has provided more detail on how its lead radiotherapy bested the standard of care in a recent phase 3 study while revealing that the candidate was unable to prove a benefit in median overall survival.
